Lipidomic profiling of exosomes from colorectal cancer cells and patients reveals potential biomarkers.

Fiche publication

Date publication

mai 2022

Journal

Molecular oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GARRIDO Carmen , Dr GOBBO Jessica , Pr ORTEGA DEBALLON Pablo , Dr PAIS DE BARROS Jean-Paul

Tous les auteurs :
Elmallah MIY, Ortega-Deballon P, Hermite L, Pais-De-Barros JP, Gobbo J, Garrido C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35524452

Résumé

Strong evidence suggests that differences in the molecular composition of lipids in exosomes depend on the cell type, has an influence on cancer initiation and progression. Here, we analyzed by liquid chromatography-mass spectrometry (LC-MS) the lipidomic signature of exosomes derived from the human cell lines normal colon mucosa (NCM460D), and colorectal cancer (CRC) non-metastatic (HCT116) and metastatic (SW620), as well as exosomes isolated from the plasma of non-metastatic and metastatic CRC patients and healthy donors. Analysis of this exhaustive lipid study highlighted changes in some molecular species that were found in the cell lines and confirmed in the patients. For example, exosomes from primary cancer patients and non-metastatic cells compared to healthy donors and control cells displayed a common marked increase in phosphatidylcholine (PC) 34:1, phosphatidylethanolamine (PE) 36:2, sphingomyelin (SM) d18:1/16:0, hexosylceramide (HexCer) d18:1/24:0 and HexCer d18:1/24:1. Interestingly, these same lipids species were decreased in the metastatic cell line and patients. Further, levels of PE 34:2, PE 36:2 and phosphorylated PE p16:0/20:4 were also significantly decreased in metastatic conditions when compared to the non-metastatic counterparts. The only molecule species found markedly increased in metastatic conditions (in both patients and cells) when compared to controls was ceramide (Cer) d18:1/24:1. These decreases in lipid species in the extracellular vesicles might reflect function-associated changes in the metastatic cell membrane. Although these potential biomarkers need to be validated in a larger cohort, they provide new insight toward the use of clusters of lipid biomarkers rather than a single molecule for the diagnosis of different stages of CRC.